365 related articles for article (PubMed ID: 15492322)
1. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Asselbergs FW; Diercks GF; Hillege HL; van Boven AJ; Janssen WM; Voors AA; de Zeeuw D; de Jong PE; van Veldhuisen DJ; van Gilst WH;
Circulation; 2004 Nov; 110(18):2809-16. PubMed ID: 15492322
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT).
Brouwers FP; Asselbergs FW; Hillege HL; de Boer RA; Gansevoort RT; van Veldhuisen DJ; van Gilst WH
Am Heart J; 2011 Jun; 161(6):1171-8. PubMed ID: 21641365
[TBL] [Abstract][Full Text] [Related]
4. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial.
Geluk CA; Asselbergs FW; Hillege HL; Bakker SJ; de Jong PE; Zijlstra F; van Gilst WH
Eur Heart J; 2005 Jul; 26(13):1314-20. PubMed ID: 15820998
[TBL] [Abstract][Full Text] [Related]
5. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.
Atthobari J; Brantsma AH; Gansevoort RT; Visser ST; Asselbergs FW; van Gilst WH; de Jong PE; de Jong-van den Berg LT;
Nephrol Dial Transplant; 2006 Nov; 21(11):3106-14. PubMed ID: 16720593
[TBL] [Abstract][Full Text] [Related]
6. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]).
Diercks GF; Janssen WM; van Boven AJ; Bak AA; de Jong PE; Crijns HJ; van Gilst WH
Am J Cardiol; 2000 Sep; 86(6):635-8. PubMed ID: 10980214
[TBL] [Abstract][Full Text] [Related]
7. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC
Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
[TBL] [Abstract][Full Text] [Related]
9. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria.
Asselbergs FW; van Roon AM; Hillege HL; de Jong PE; Gans RO; Smit AJ; van Gilst WH;
Stroke; 2005 Mar; 36(3):649-53. PubMed ID: 15692120
[TBL] [Abstract][Full Text] [Related]
10. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects.
Asselbergs FW; van der Harst P; van Roon AM; Hillege HL; de Jong PE; Gans ROB; Smit AJ; van Gilst WH
Atherosclerosis; 2008 Jan; 196(1):349-355. PubMed ID: 17141245
[TBL] [Abstract][Full Text] [Related]
12. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients.
van de Wal RM; Gansevoort RT; van der Harst P; Boomsma F; Thijs Plokker HW; van Veldhuisen DJ; de Jong PE; van Gilst WH; Voors AA
Hypertension; 2006 Nov; 48(5):870-6. PubMed ID: 17000930
[TBL] [Abstract][Full Text] [Related]
13. Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects.
van de Wal RM; van der Harst P; Gerritsen WB; van der Horst F; Plokker TH; Gansevoort RT; van Gilst WH; Voors AA
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):177-80. PubMed ID: 18205096
[TBL] [Abstract][Full Text] [Related]
14. The effects of a low-dose regimen of fosinopril on elevated urinary albumin excretion in normotensive type 1 diabetic patients.
Carella MJ; Gossain VV; Jones J
J Med; 1999; 30(5-6):305-20. PubMed ID: 10851564
[TBL] [Abstract][Full Text] [Related]
15. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Packard CJ; Ford I; Robertson M; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
Circulation; 2005 Nov; 112(20):3058-65. PubMed ID: 16275871
[TBL] [Abstract][Full Text] [Related]
16. Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria.
van der Harst P; Asselbergs FW; Hillege HL; Voors AA; van Veldhuisen DJ; van Gilst WH;
Am J Cardiol; 2008 Jul; 102(2):223-5. PubMed ID: 18602526
[TBL] [Abstract][Full Text] [Related]
17. Effect of pravastatin in people with diabetes and chronic kidney disease.
Tonelli M; Keech A; Shepherd J; Sacks F; Tonkin A; Packard C; Pfeffer M; Simes J; Isles C; Furberg C; West M; Craven T; Curhan G
J Am Soc Nephrol; 2005 Dec; 16(12):3748-54. PubMed ID: 16251235
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
Brantsma AH; Bakker SJ; Hillege HL; de Zeeuw D; de Jong PE; Gansevoort RT;
Nephrol Dial Transplant; 2008 Dec; 23(12):3851-8. PubMed ID: 18641082
[TBL] [Abstract][Full Text] [Related]
19. [Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor].
Durruty P; Tapia JC; Ugarte C; Pérez E; Krause P; Soto N; García de los Ríos M
Rev Med Chil; 1996 Sep; 124(9):1036-44. PubMed ID: 9197016
[TBL] [Abstract][Full Text] [Related]
20. Effect of pravastatin on blood pressure in people with cardiovascular disease.
Tonelli M; Sacks F; Pfeffer M; Lopez-Jimenez F; Jhangri GS; Curhan G
J Hum Hypertens; 2006 Aug; 20(8):560-5. PubMed ID: 16625234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
